-
Summary
Cancer is a highly dangerous disease that seriously threatens human life. It is currently the second leading cause of death worldwide. In 2020, cancer was responsible for nearly 10 million deaths globally, and it is projected to become the leading cause of death in the coming years. These statistics highlight the urgent need for effective measures to prevent and treat cancer. This project aims to prepare multivalent carbonic anhydrase inhibitors, which are expected to be more effective than monovalent carbonic anhydrase inhibitors in the treatment of cancer disease. Carbonic anhydrase inhibitors (CAIs) are important because they have a wide range of therapeutic applications. Carbonic anhydrase enzyme catalyzes the reversible hydration of CO2 to bicarbonate ions and protons. This enzyme plays an important role in the regulation of acid-base balance in the body, as well as in the secretion of fluids and electrolytes. CAIs are a class of drugs that inhibit carbonic anhydrase activity, leading to a decrease in the production of bicarbonate ions and protons. This inhibition can have therapeutic benefits for a variety of conditions, including Glaucoma, Edema, Epilepsy, Osteoporosis, and Cancer. Multivalent interaction of several inhibitory binding units can enhance the binding affinity and selectivity. This is because the multiple binding units can interact with multiple binding sites on a target molecule simultaneously, increasing the overall strength of the interaction. Thus, the multivalent approach may open new opportunities in the drug design of innovative isoform-selective carbonic anhydrase inhibitors with biomedical applications. Oligonucleotides have therapeutic applications, especially in the development of antisense oligonucleotides, which are designed to bind to specific mRNA sequences and prevent the production of specific proteins. This approach has shown promise in inhibition of carbonic anhydrase and the treatment of various diseases, including cancer. In our work, we target to design, synthesize and characterize multivalent CAIs using oligonucleotide scaffolds by a powerful synthetic strategy that allows for the rapid and efficient construction of complex molecular architectures (click chemistry) and use it in cancer therapy.
-
Achievements
-
List of Publications from the Project
-
Partners
-
Project Members
-
Project Leaders
-
Project PI
-
Faculty
Faculty of Science
-
Research Group
-
Funding Agency
STDF / STIFA
-
Funding Program
Egypt-France Cooperation
-
Start Date
2024-07-01
-
End Date
2025-02-01
-
Sustainable Development Goals (SDGs)
- 3: Good Health and Well-being
-
Project website